Navigation Links
Welsh shingles drug set for final hurdle
Date:3/23/2010

A new Welsh-developed drug to help alleviate the suffering of shingles could move a step closer for patients if the final stage of testing is given the go-ahead.

A new shingles drug (FV-100), discovered by Professor Chris McGuigan's team from Cardiff University's Welsh School of Pharmacy together with a virology group at the Rega Institute in Belgium and US biopharmaceutical company, Inhibitex Inc, is due to complete Phase II of its clinical trials.

If the drug completes Phase II it will enter the third and final stage which could see the drug being available to patients in less than three years.

Cardiff University's Professor of Medical Chemistry, Chris McGuigan, who led the team which discovered the new antiviral drug, said: "We are now entering the final and most crucial stage in the journey from the discovery of a new drug to the market.

"If we successfully complete this stage the drug would be available to help alleviate the pain and suffering for millions of shingles patients, not only in Wales but across the world."

Shingles is caused by the same viral infection that causes chicken pox. It is estimated that one-in-five people in the US, Europe and Japan will be affected by the condition during their lifetime.

The condition is characterised by skin lesions, blisters and rash, and acute pain, and in many cases, post-herpetic neuralgia which is a painful and often highly distressing condition resulting from nerve damage caused by the virus. Initial tests of FV-100 showed it has the potential to greatly reduce all of these symptoms.

In Phase I trials of FV-100, no serious adverse events in healthy volunteers were reported and data supported the potential for once-a-day dosing in future trials.Previous lab research has also shown the drug to be up to 10,000 times more potent against the virus than existing treatments.

Professor McGuigan added: "We believe this drug has the poten
'/>"/>

Contact: Chris Jones
JonesC83@cardiff.ac.uk
44-292-087-4731
Cardiff University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Welsh Tree LLC Proudly Presents the Release of the Celtic Pathways CD by Jason Evans, in Time for Saint Patrick's Day
2. Chicken Pox Shot Protects Against Shingles, Too
3. Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children
4. Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco
5. AKON Fragrance Finally Available at Akonfragrances.com
6. Morehead Associates, Inc. and Child Health Corporation of America (CHCA) Finalize Agreement for Employee and Physician Surveys and Consulting Services
7. Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th
8. 21 Healthcare Companies Achieve Semi-Finalist Status for Innovations in HealthcareSM ABBY Awards
9. Neovasc Completes Final Tranche of $1.537 Million Non-Brokered Private Placement
10. Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration
11. Kiwanis Selects Three Finalists for Worldwide Service Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... to prevent Ebola virus disease will begin next week ... (NIAID), part of the National Institutes of Health. , ... a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) and ... generate an immune system response in healthy adults. Testing ... Bethesda, Maryland. , The study is the first of ...
(Date:8/28/2014)... patients in the study who were on a class ... them as prescribed in the first six months. Patients ... hospitals around the UK involved in the study. , ... and Genomics at The University of Manchester, who led ... correctly, known as ,non-adherence, reduced their effectiveness and may ...
(Date:8/28/2014)... AmeriPride Services, a leading textile services and supply ... its new Customer Portal, an online resource that makes ... for customers. The industry-leading digital tool allows customers to ... company. , Features of the new customer portal include ... and pay bills online , View delivery ...
(Date:8/28/2014)... 2014 Clarity PSO , an ... as a federal Patient Safety Organization (PSO) for another ... Healthcare Research and Quality (AHRQ). Clarity PSO will continue ... services following the true intentions of the Patient Safety ... are proud and eager to continue our journey as ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Genetic ... available throughout the world, with large reference laboratories ... Since laboratories differ with regard to the genetic ... costs, payers may struggle to find the most ... To help clients sort through these differences, Hayes, ...
Breaking Medicine News(10 mins):Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5Health News:Arthritis patients failing to take expensive medication, according to new research 2Health News:AmeriPride Services Launches New Customer Portal 2Health News:AmeriPride Services Launches New Customer Portal 3Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 2Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 3Health News:Hayes, Inc. Unveils Laboratory Comparison Tables for GTE Clients 2
... Parents of children with allergies are prone to increased ... ,According to foodconsumer.org, children of parents who ... according to a new study by researchers at Cincinnati ... for allergies are twice as likely to snore. ...
... study conducted on 2500 patients has suggested that women who ... dementia. A Mayo Clinic, Minnesota team has revealed that young ... the age of 38, face a risk enhanced by 260%. ... Neurology. ,Researchers have zeroed in on the possible reason ...
... friend who was a colleague of the murdered nurse, Cheryl Moss ... killed. //When speaking to the press outside the St George's Hospital ... on the Canvey ward. She said that Cheryl was desperate to ... that one among them was murdered in the common smoking spot. ...
... is a genetic disorder that affects the heart's largest artery, ... bottom of the disease and researchers at Johns Hopkins University// ... the blood-pressure drug that has shown promise in recent studies ... Hopkins University said that the Merck's drug appears to prevent ...
... to the fumes of solvents used in house renovations.Contact ... give rise to allergies in young children, said Norbert ... ,Pregnant women should leave renovation work to ... the work area altogether. ,'It is also ...
... culling of poultry began in Niger one of the world’s ... an outbreak of deadly// avian flu near its southern border ... culling of all poultry in affected areas on February 28, ... has now appealed for international help, as it lacked the ...
Cached Medicine News:Health News:Children Of Snoring Parents Are More Likely To Inherit Themselves 2Health News:Cognitive Impairment or Dementia Risk, Pronounced with Ovary loss 2Health News:Delayed Start By Niger On Culling Of Poultry 2Health News:Delayed Start By Niger On Culling Of Poultry 3
(Date:8/28/2014)... , Aug. 28, 2014  Sequent Medical, ... enrollment in an Investigational Device Exemption ("IDE") pivotal ... the WEB™ Aneurysm Embolization System ("WEB"). Adam ... Department of Neurosurgery/Semmes-Murphey Clinic and Principal Investigator of ... the study, treating them with the WEB at ...
(Date:8/28/2014)... 28, 2014 GenSpera, Inc. (OTCQB: GNSZ), a ... cancer, announces the recent publication of the article "Targeting ... The recent article co-authored by Doan, et ... of GenSpera,s prodrug technology platform that is designed to ... plant Thapsia garganica ) directly to tumors. These ...
(Date:8/28/2014)... , Aug. 28, 2014 Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced today ... of cGMP manufacturing of SYN-004, Synthetic Biologics, proprietary ... Clostridium difficile ( C. difficile ) infections. ...
Breaking Medicine Technology:Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 2Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 3GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 4Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 5
... TRACON Pharmaceuticals, a biotechnology company that develops targeted ... Phase 1 clinical results from studies of TRC105 and ... at the American Society of Clinical Oncology annual meeting ... programs target unique pathways with the potential for broad ...
... Ascenta Therapeutics announced today that eleven presentations or publications ... pan-Bcl-2 inhibitor, in several major tumor types will be ... (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida. ... .(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ...
Cached Medicine Technology:TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 3
... The Isoseeds I-125 are brachytherapy sources which ... of localized tumors, especially in the prostate. ... the conclusion of the therapeutic effect, i.e. ... are intended for single use. They are ...
... Four 64 mirrors for complete ... lens rotation. Directly hand held for ... or small holding ring. Small diameter ... gonioscopy without methylcellulose. Advanced technology, multi-layer ...
... Three mirrors of 64, ... small diameter contact surface for ... can be viewed through the ... Multi-layer polymer coating protects mirrors ...
West lacrimal cannula blunt tip with side port....
Medicine Products: